Fibronostics Expands U.S. Operations with Stone Clinical Laboratories Acquisition

Fibronostics, a leader in non-invasive diagnostics for metabolic and liver diseases, has completed its acquisition of Stone Clinical Laboratories, LLC. This strategic move, announced on October 27, 2025, significantly enhances Fibronostics’ U.S. laboratory operations and accelerates its innovation in diagnostics for metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD).

The acquisition occurs during a transformative period for the industry, marked by pivotal advancements such as the FDA approvals of Madrigal Pharmaceuticals‘ RezdiffraTM and Novo Nordisk‘s Wegovy®. Additionally, Roche‘s acquisition of 89Bio underscores the increasing investment in MASH and MASLD therapeutics. These developments reveal a growing need for reliable diagnostics that can accurately identify patients, track disease progression, and monitor treatment outcomes.

In a statement regarding the acquisition, Brock Smith, Chief Executive Officer of Fibronostics, emphasized the expanded laboratory infrastructure and operational expertise gained through the merger. “This strengthens our ability to accelerate innovation in non-invasive diagnostics and enhance collaborations with pharmaceutical and healthcare partners addressing the global burden of MASH and MASLD,” Smith noted.

Stone Clinical Laboratories brings valuable technical expertise and robust testing capabilities that will complement Fibronostics’ existing digital health platforms, including LIVERFASt®. This collaboration aims to advance biomarker development, research and development programs, and clinical validation studies that support therapeutic innovation and patient management.

Smith further stated, “Therapeutic breakthroughs in MASH and MASLD are reshaping liver care. As treatment options expand, the need for precise and accessible diagnostics becomes more critical.” He added that this acquisition positions Fibronostics to lead in providing scalable solutions that integrate diagnostics with therapeutics.

This acquisition is a significant milestone for Fibronostics as it aims to bolster its growth strategy. The newly combined organization is poised to work closely with biopharma innovators, healthcare systems, and payers. The goal is to accelerate early detection and improve health outcomes for patients around the world.

Fibronostics is recognized as a global health technology company specializing in non-invasive diagnostic solutions for chronic diseases, particularly in the realm of liver and metabolic disorders. Its flagship platform, LIVERFASt®, allows clinicians to assess liver health efficiently and accurately. The company collaborates with global pharmaceutical firms, diagnostic laboratories, and healthcare systems to enhance the next generation of liver diagnostics, ultimately improving patient outcomes on a global scale.

For further information, contact:
Brock Smith
Chief Executive Officer
Fibronostics US Inc.
Phone: 1-888-552-1603
Email: [email protected]